1. history of severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers), or other coronavirus infections at any time; 2. history of hepatitis a, hepatitis b, hepatitis c, syphilis infection based on medical inquiry.; 3. history of severe adverse reaction associated with a vaccine or drug and/or severe allergic reaction (e.g., anaphylaxis) to any component of the study intervention(s); 4. receipt of medications intended to treat covid-19 within 6 months; 5. virologically confirmed sars-cov-2 diagnosis within 6 months before screening visit; 6. positive nasopharyngeal/oropharyngeal swab sars-cov-2 rt-pcr test result at screening; 7. positive hiv test result at screening; 8. a history or family history of convulsions, epilepsy, encephalopathy and psychosis; 9. malignant tumors in the active phase, malignant tumors not receiving adequate treatment, malignant tumors at potential risk of recurrence during the study period; 10. asplenia or functional asplenia, complete or partial splenectomy from any cause; 11. individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids (if systemic corticosteroids are administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent), e.g., for cancer or an autoimmune disease, or planned receipt throughout the study. inhaled/nebulized, intra-articular, epidural, or topical (skin or eyes) corticosteroids are permitted; 12. any other licensed vaccines given within 28 days prior to vaccination, planned administration of any other vaccines within 28 days after vaccination, or planned administration of other covid-19 vaccines during the entire study duration; 13. receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before vaccine administration, or receipt of any passive antibody therapy specific to covid-19, from 90 days before vaccine administration, or planned receipt throughout the study; 14. blood donation or blood loss ≥ 450 ml within 1 month prior to enrollment or planned to donate blood during the study period; 15. participation in other studies involving study intervention within 28 days prior to study entry, and/or during the study; 16. women who are pregnant or breastfeeding; 17. participants deemed unsuitable for participation in this study based on the investigator's assessment.

1. history of severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers), or other coronavirus infections at any time; 2. history of hepatitis a, hepatitis b, hepatitis c, syphilis infection based on medical inquiry.; 3. history of severe adverse reaction associated with a vaccine or drug and/or severe allergic reaction (e.g., anaphylaxis) to any component of the study intervention(s); 4. receipt of medications intended to treat covid-19 within 6 months; 5. virologically confirmed sars-cov-2 diagnosis within 6 months before screening visit; 6. positive nasopharyngeal/oropharyngeal swab sars-cov-2 rt-pcr test result at screening; 7. positive hiv test result at screening; 8. a history or family history of convulsions, epilepsy, encephalopathy and psychosis; 9. malignant tumors in the active phase, malignant tumors not receiving adequate treatment, malignant tumors at potential risk of recurrence during the study period; 10. asplenia or functional asplenia, complete or partial splenectomy from any cause; 11. individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids (if systemic corticosteroids are administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent), e.g., for cancer or an autoimmune disease, or planned receipt throughout the study. inhaled/nebulized, intra-articular, epidural, or topical (skin or eyes) corticosteroids are permitted; 12. any other licensed vaccines given within 28 days prior to vaccination, planned administration of any other vaccines within 28 days after vaccination, or planned administration of other covid-19 vaccines during the entire study duration; 13. receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before vaccine administration, or receipt of any passive antibody therapy specific to covid-19, from 90 days before vaccine administration, or planned receipt throughout the study; 14. blood donation or blood loss ≥ 450 ml within 1 month prior to enrollment or planned to donate blood during the study period; 15. participation in other studies involving study intervention within 28 days prior to study entry, and/or during the study; 16. women who are pregnant or breastfeeding; 17. participants deemed unsuitable for participation in this study based on the investigator's assessment.

history of severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers), or other coronavirus infections at any time; history of hepatitis a, hepatitis b, hepatitis c, syphilis infection based on medical inquiry.; history of severe adverse reaction associated with a vaccine or drug and/or severe allergic reaction (e.g., anaphylaxis) to any component of the study intervention(s); receipt of medications intended to treat covid-19 within 6 months; virologically confirmed sars-cov-2 diagnosis within 6 months before screening visit; positive nasopharyngeal/oropharyngeal swab sars-cov-2 rt-pcr test result at screening; positive hiv test result at screening; a history or family history of convulsions, epilepsy, encephalopathy and psychosis; malignant tumors in the active phase, malignant tumors not receiving adequate treatment, malignant tumors at potential risk of recurrence during the study period; asplenia or functional asplenia, complete or partial splenectomy from any cause; individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids (if systemic corticosteroids are administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent), e.g., for cancer or an autoimmune disease, or planned receipt throughout the study. inhaled/nebulized, intra-articular, epidural, or topical (skin or eyes) corticosteroids are permitted; any other licensed vaccines given within 28 days prior to vaccination, planned administration of any other vaccines within 28 days after vaccination, or planned administration of other covid-19 vaccines during the entire study duration; receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before vaccine administration, or receipt of any passive antibody therapy specific to covid-19, from 90 days before vaccine administration, or planned receipt throughout the study; blood donation or blood loss ≥ 450 ml within 1 month prior to enrollment or planned to donate blood during the study period; participation in other studies involving study intervention within 28 days prior to study entry, and/or during the study; women who are pregnant or breastfeeding; participants deemed unsuitable for participation in this study based on the investigator's assessment.

history of severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers), or other coronavirus infections at any time; history of hepatitis a, hepatitis b, hepatitis c, syphilis infection based on medical inquiry.; history of severe adverse reaction associated with a vaccine or drug and/or severe allergic reaction (e.g., anaphylaxis) to any component of the study intervention(s); receipt of medications intended to treat covid-19 within 6 months; virologically confirmed sars-cov-2 diagnosis within 6 months before screening visit; positive nasopharyngeal/oropharyngeal swab sars-cov-2 rt-pcr test result at screening; positive hiv test result at screening; a history or family history of convulsions, epilepsy, encephalopathy and psychosis; malignant tumors in the active phase, malignant tumors not receiving adequate treatment, malignant tumors at potential risk of recurrence during the study period; asplenia or functional asplenia, complete or partial splenectomy from any cause; individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids (if systemic corticosteroids are administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent), e.g., for cancer or an autoimmune disease, or planned receipt throughout the study. inhaled/nebulized, intra-articular, epidural, or topical (skin or eyes) corticosteroids are permitted; any other licensed vaccines given within 28 days prior to vaccination, planned administration of any other vaccines within 28 days after vaccination, or planned administration of other covid-19 vaccines during the entire study duration; receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before vaccine administration, or receipt of any passive antibody therapy specific to covid-19, from 90 days before vaccine administration, or planned receipt throughout the study; blood donation or blood loss ≥ 450 ml within 1 month prior to enrollment or planned to donate blood during the study period; participation in other studies involving study intervention within 28 days prior to study entry, and/or during the study; women who are pregnant or breastfeeding; participants deemed unsuitable for participation in this study based on the investigator's assessment.